News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

CMC Contrast AB Appoints Patrick Greatrex as Chief Executive Officer


5/29/2012 8:34:40 AM

Lund, Sweden, May 28, 2012 -- CMC Contrast AB, a privately owned drug development company that specializes in developing targeted contrast media for Magnetic Resonance Imaging (MRI), announced today that it has appointed Patrick Greatrex, as its new Chief Executive Officer (CEO). Patrick Greatrex, an experienced life science executive, was most recently Deputy CEO of Glycorex Transplantation AB, a medical device company active in the area of organ transplantation. Prior to joining Glycorex Transplantation, Patrick was Vice President of Business Development at Gambro AB. Patrick has Bachelor Degrees in Law and Arts from the University of Queensland, Australia and an Executive M.B.A. from Lund University, Sweden.

"I am very happy to welcome Patrick Greatrex to CMC Contrast." says Magnus Corfitzen, CMC Contrast’s Chairman. “Patrick has a very strong business development background in both large and smaller life science companies. He has held a number of leading positions and has been involved in securing funding, acquiring and divesting companies, designing clinical trials, launching innovative products and driving sales activities. He joins CMC Contrast at a very exciting time as we begin our phase 3 trial and prepare for commercialisation.”

"I am truly excited to join CMC Contrast.” says Patrick Greatrex. “It is a privilege to work with a late stage drug development opportunity with convincing clinical data. The experienced Board and Management Team of CMC Contrast have set a clear strategy which is motivating. As we move into an exciting Phase 3 clinical development program, I look forward to strengthening our clinical development capabilities and working with the team at CMC Contrast in realising our vision.”

About CMC Contrast

CMC Contrast AB is a privately owned drug development company that specializes in developing targeted contrast media for Magnetic Resonance Imaging (MRI). CMC Contrast’s first product, CMC 001, is the world’s first oral contrast agent for MRI of the liver. CMC 001 is an oral manganese-based contrast which enables safe and excellent liver enhancement in MRI, without the risks associated with gadolinium based contrast media.

For further details please contact

Magnus Corfitzen

Chairman CMC Contrast AB

Sunstone Capital

Mobile: +45 4080 4863

Email: corfitzen@sunstonecapital.com

Patrick Greatrex

Chief Executive Office CMC Contrast AB

Mobile: +46 720 173 163

Email: pg@cmc-contrast.dk


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES